ROIVANT SCIENCES LTD. Increase (Decrease) in Accounts Payable, Trade
ROIVANT SCIENCES LTD. (ROIV) reported Increase (Decrease) in Accounts Payable, Trade of $7.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-06
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $7.11M.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $16.16M.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$3.99M, a 7485.19% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $3.00M, a 58.45% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for fiscal 2026 was $3.42M.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for fiscal 2025 was -$18.17M, a 180.09% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for fiscal 2024 was $22.68M, a 420.39% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. increase (decrease) in accounts payable, trade for fiscal 2023 was $4.36M, a 71.70% decline from fiscal 2022.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.11M 10-Q · filed 2026-08-06 | $23.26M derived: sum of 2 quarters · filed 2026-08-06 | $19.28M derived: sum of 3 quarters · filed 2026-08-06 | $22.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $12.17M derived: sum of 2 quarters · filed 2026-05-20 | $15.16M derived: sum of 3 quarters · filed 2026-05-20 | $3.42M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$992.00K derived: sum of 2 quarters · filed 2026-02-06 | -$12.74M 10-Q · filed 2026-02-06 | -$12.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$8.75M 10-Q · filed 2025-11-10 | -$8.91M derived: sum of 3 quarters · filed 2026-08-06 | -$8.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$11.74M 10-Q · filed 2026-08-06 | -$11.91M derived: sum of 2 quarters · filed 2026-08-06 | -$11.86M derived: sum of 3 quarters · filed 2026-08-06 | -$4.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$111.00K derived: sum of 2 quarters · filed 2026-05-20 | $7.10M derived: sum of 3 quarters · filed 2026-05-20 | -$18.17M 10-K · filed 2026-05-20 |
| 2024-12-31 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $7.26M derived: sum of 2 quarters · filed 2026-02-06 | -$18.00M 10-Q · filed 2026-02-06 | $2.88M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$18.06M 10-Q · filed 2025-11-10 | $2.83M derived: sum of 3 quarters · filed 2026-05-20 | -$5.51M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$25.27M 10-Q · filed 2025-08-11 | -$4.38M derived: sum of 2 quarters · filed 2026-05-20 | -$12.72M derived: sum of 3 quarters · filed 2026-05-20 | -$14.52M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $20.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $12.54M derived: sum of 2 quarters · filed 2026-05-20 | $10.74M derived: sum of 3 quarters · filed 2026-05-20 | $22.68M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | -$10.14M derived: sum of 2 quarters · filed 2025-02-10 | $1.80M 10-Q · filed 2025-02-10 | -$7.81M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $10.14M 10-Q · filed 2024-11-12 | $531.00K derived: sum of 3 quarters · filed 2025-05-29 | $7.73M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $11.94M 10-Q · filed 2024-08-09 | $2.33M derived: sum of 2 quarters · filed 2025-05-29 | $9.53M derived: sum of 3 quarters · filed 2025-05-29 | $35.75M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$2.42M derived: sum of 2 quarters · filed 2025-05-29 | $23.81M derived: sum of 3 quarters · filed 2025-05-29 | $4.36M 10-K · filed 2025-05-29 |
| 2022-12-31 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $33.42M derived: sum of 2 quarters · filed 2024-02-13 | $13.97M 10-Q · filed 2024-02-13 | $25.68M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $26.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $6.77M 10-Q · filed 2023-11-13 | $18.48M derived: sum of 3 quarters · filed 2023-11-13 | -$34.33M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$19.45M 10-Q · filed 2023-08-14 | -$7.74M derived: sum of 2 quarters · filed 2023-08-14 | -$60.56M derived: sum of 3 quarters · filed 2023-08-14 | $2.29M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$41.11M derived: sum of 2 quarters · filed 2023-06-28 | $21.75M derived: sum of 3 quarters · filed 2023-06-28 | $15.40M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$52.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $10.04M derived: sum of 2 quarters · filed 2023-02-13 | $3.69M 10-Q · filed 2023-02-13 | $10.15M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $62.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $56.51M 10-Q · filed 2022-11-14 | $62.96M derived: sum of 3 quarters · filed 2022-11-14 | $60.29M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$6.34M 10-Q · filed 2022-08-15 | $111.00K derived: sum of 2 quarters · filed 2022-08-15 | -$2.56M derived: sum of 3 quarters · filed 2022-08-15 | -$10.09M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $3.78M derived: sum of 2 quarters · filed 2022-06-28 | -$3.75M derived: sum of 3 quarters · filed 2022-06-28 | $3.75M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | -$10.20M derived: sum of 2 quarters · filed 2022-02-14 | -$2.70M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$7.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$29.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $7.50M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |